TrialBlood advances2026

Gilteritinib and chemotherapy in children with relapsed/refractory FLT3-ITD AML: results from the phase 1/2 SKIPPER trial.

Philip Connor et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.